Premium
Incretin‐based therapies for the treatment of non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
Author(s) -
Carbone Laura J,
Angus Peter W,
Yeomans Neville D
Publication year - 2016
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.13026
Subject(s) - medicine , steatosis , fatty liver , incretin , gastroenterology , meta analysis , alanine transaminase , diabetes mellitus , disease , type 2 diabetes , endocrinology
Background and Aim: Non‐alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease in Western societies. Despite its significance, there are no well‐proven pharmacological treatments. Two novel classes of potential pharmacotherapies are the glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and dipeptidyl peptidase‐4 inhibitors (DPP‐4I), collectively known as incretin‐based therapies. These have several metabolic and anti‐inflammatory actions that may be of benefit in NAFLD. The aim of this meta‐analysis was to evaluate their efficacy via a structured retrieval and pooled analysis of relevant studies. Methods: Studies were sourced from electronic databases and meeting abstracts. Main inclusion criteria were original studies investigating treatment of adults with NAFLD using GLP‐1 RA/DPP‐4I. Key outcomes were a change in serum alanine transaminase (ALT), as a marker of liver inflammation, and improvement in disease status measured by imaging or histology. Results: Initial searching retrieved 1357 peer‐reviewed articles and abstracts. Four studies met all inclusion and exclusion criteria. There were a total of 136 participants with NAFLD and concomitant type 2 diabetes mellitus (T2DM). Meta‐analysis (random‐effects model) revealed a significant decrease in serum ALT following treatment (mean reduction 14.1 IU/L, 95% confidence intervals [CI] 8.3–19.8, P < 0.0001). In two studies with imaging and tissue data, treatment was found to significantly reduce steatosis, inflammation, and fibrosis. Conclusion: The significant decrease in a key biochemical marker of hepatic inflammation following treatment with incretin‐based therapies, as well as improvements in imaging and histology, suggests these agents may be effective options for managing NAFLD with comorbid T2DM.